Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07226557 · ClinicalTrials.gov registry record
Cefiderocol vs Best Available Therapy for Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex Infections: A Target Trial Emulation
A clinical trial of Antimicrobial Drug Resistance and Carbapenem Resistant Bacterial Infection, sponsored by National Institutes of Health Clinical Center (CC).
- Active
- Registry status
- 5,000
- Enrollment target
- 1
- Study location
NCT07226557: Active study of Antimicrobial Drug Resistance and Carbapenem Resistant Bacterial Infection, sponsored by National Institutes of Health Clinical Center (CC).
NCT07226557 is a study of Antimicrobial Drug Resistance and Carbapenem Resistant Bacterial Infection that is active but no longer recruiting, run by National Institutes of Health Clinical Center (CC). The registered enrollment target is 5,000 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07226557, a study of Antimicrobial Drug Resistance and Carbapenem Resistant Bacterial Infection, is active but no longer recruiting, sponsored by National Institutes of Health Clinical Center (CC).
- ACTIVE NOT RECRUITING
- Registry status
- 5,000 participants
- Enrollment target
- 1
- Study location
Study Summary
This study aims to compare 28-day mortality among patients with carbapenem resistant A. baumannii infections in two hypothetical target trials where patients receive 7 days of a cefiderocol-based treatment strategy or 7 days of a best available therapy treatment strategy.
Primary Outcome
In hospital mortality or discharge to hospice during the hospital stay
Conditions Studied
Study Locations (1)
Maryland
- National Institutes of Health Clinical Center - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,000 participants |
| Start Date | 2025-01-01 |
| Est. Completion | 2025-12-31 |
What the registry record for NCT07226557 still lists
NCT07226557 is an observational study that tracks outcomes without assigning an intervention. Its 5,000 participants enrollment target places it among the larger protocols in the corpus.
The record links to 3 conditions, with Antimicrobial Drug Resistance appearing as the primary indexed condition, and to 0 interventions.
NCT07226557 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT07226557 about?
NCT07226557 is a clinical study titled "Cefiderocol vs Best Available Therapy for Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex Infections: A Target Trial Emulation". This study aims to compare 28-day mortality among patients with carbapenem resistant A. baumannii infections in two hypothetical target trials where patients receive 7 days of a cefiderocol-based treatment strategy or 7 days of a best available therapy treatment strategy.
What is the current status of trial NCT07226557?
This trial is currently active not recruiting. The enrollment target is 5,000 participants. The study started on 2025-01-01. Estimated completion is 2025-12-31.
What conditions does trial NCT07226557 study?
This clinical trial studies the following conditions: Antimicrobial Drug Resistance, Carbapenem Resistant Bacterial Infection, Acinetobacter Baumannii Infection.
Who is sponsoring clinical trial NCT07226557?
This trial is sponsored by National Institutes of Health Clinical Center (CC), which has 338 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07226557 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Antimicrobial Drug Resistance
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00060541 · 5,000 participants
Evaluation and Treatment of Neurosurgical Disorders
- NCT00575081 · 5,000 participants
Physiological Brain Atlas Development
- NCT00736749 · 5,000 participants
Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies
- NCT00900198 · 5,000 participants
Collection of Tissue Samples for Cancer Research
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI